Juan Carlos Ramirez
Overview
Explore the profile of Juan Carlos Ramirez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
759
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lopez-Albizu C, Cura C, Ramirez J, Peyran P, Benchetrit A, Danesi E, et al.
PLoS Negl Trop Dis
. 2025 Jan;
19(1):e0012785.
PMID: 39792926
Background: Trypanosoma cruzi is a protozoan parasite which causes Chagas disease. Mother-to-child transmission is the main route of transmission in vector-free areas. Congenital Chagas disease refers specifically to cases arising...
2.
Arrasate A, Bravo I, Lopez-Robles C, Arbelaiz-Sarasola A, Ugalde M, Meijueiro M, et al.
Biomedicines
. 2024 Oct;
12(10).
PMID: 39457578
To date, nearly 300 lentiviral-based gene therapy clinical trials have been conducted, with eight therapies receiving regulatory approval for commercialization. These advances, along with the increased number of advanced-phase clinical...
3.
Banos-Mateos S, Lopez-Robles C, Yubero M, Jurado A, Arbelaiz-Sarasola A, Lamsfus-Calle A, et al.
Viruses
. 2024 Aug;
16(8).
PMID: 39205190
Transduction of producer cells during lentiviral vector (LVV) production causes the loss of 70-90% of viable particles. This process is called retro-transduction and it is a consequence of the interaction...
4.
Geist B, Ramirez J, Binder P, Einspieler H, Ibeschitz H, Langsteger W, et al.
EJNMMI Res
. 2024 May;
14(1):46.
PMID: 38750398
Background: Approaches targeting the sodium-glucose cotransporter (SGLT) could represent a promising future therapeutic strategy for numerous oncological and metabolic diseases. In this study, we evaluated the safety, biodistribution and radiation...
5.
Moscatelli G, Moroni S, Ramirez J, Warszatska B, Fernanda L, Gonzalez N, et al.
PLoS Negl Trop Dis
. 2024 Jan;
18(1):e0011895.
PMID: 38252673
Background: In regions with controlled vector transmission of T. cruzi, congenital transmission is the most frequent route of infection. Treatment with benznidazole (BZ) or nifurtimox (NF) for 60 days in...
6.
Bosch-Nicolau P, Fernandez M, Sulleiro E, Villar J, Perez-Molina J, Correa-Oliveira R, et al.
Lancet Infect Dis
. 2024 Jan;
24(4):386-394.
PMID: 38218195
Background: Treatment with benznidazole for chronic Chagas disease is associated with low cure rates and substantial toxicity. We aimed to compare the parasitological efficacy and safety of 3 different benznidazole...
7.
Pinazo M, Forsyth C, Losada I, Esteban E, Garcia-Rodriguez M, Villegas M, et al.
Lancet Infect Dis
. 2024 Jan;
24(4):395-403.
PMID: 38218194
Background: More than six million people worldwide, particularly in vulnerable communities in Latin America, are infected with Trypanosoma cruzi, the causative agent of Chagas disease. Only a small portion have...
8.
Anzola L, Rivera J, Ramirez J, Signore A, Mut F
J Clin Med
. 2021 Dec;
10(23).
PMID: 34884218
Atherosclerosis is responsible for the majority of heart attacks and is characterized by several modifications of the arterial wall including an inflammatory reaction. The silent course of atherosclerosis has made...
9.
Ramirez J, Acevedo G, Torres C, Parrado R, De La Barra A, Villarroel S, et al.
J Antimicrob Chemother
. 2021 Dec;
77(3):578-584.
PMID: 34865002
Background: The role that the genetic diversity of natural Trypanosoma cruzi populations plays in response to trypanocidal treatment of chronic Chagas disease (CD) patients remains to be understood. We analysed...
10.
Benatar A, Danesi E, Besuschio S, Bortolotti S, Cafferata M, Ramirez J, et al.
EBioMedicine
. 2021 Jun;
69:103450.
PMID: 34186488
Background: Current algorithm for Congenital Chagas Disease (cCD) diagnosis is unsatisfactory due to low sensitivity of the parasitological methods. Moreover, loss to follow-up precludes final serodiagnosis after nine months of...